| Mark Andrew Benedict, DO | |
|
1400 N 500 E, Logan, UT 84341-2455 | |
| (435) 716-4103 | |
| Not Available |
| Full Name | Mark Andrew Benedict |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 11 Years |
| Location | 1400 N 500 E, Logan, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497191860 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 10581549-1204 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Logan Regional Hospital | Logan, UT | Hospital |
| Franklin County Medical Center | Preston, ID | Hospital |
| Intermountain Medical Center | Murray, UT | Hospital |
| Cassia Regional Hospital | Burley, ID | Hospital |
| Bear River Valley Hospital | Tremonton, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Utah Pathology Services Inc | 1355251521 | 27 |
News Archive
New research pertaining to the latest findings on the effects of epilepsy on both the mother and child were presented at the American Epilepsy Society's 67th Annual Meeting in Washington DC. These studies explore folic acid use, the effect of surgery with intractable focal epilepsy, and antiepileptic drug exposure during breastfeeding.
Dr. Akhilesh K. Gaharwar, associate professor, has developed a highly printable bioink as a platform to generate anatomical-scale functional tissues. This study was recently published in the American Chemical Society's Applied Materials and Interfaces.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject "mid strength" dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.
According to current estimates, 20 to 25 million Americans have or will develop gallstones, representing almost 15% of adults. Although only a small percentage of individuals with gallstones develop symptoms, more than 700,000 individuals annually undergo surgical gallbladder removal and many more take medications to manage the condition or undergo stone-dissolving procedures.
› Verified 1 days ago
| Entity Name | Utah Pathology Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134188998 PECOS PAC ID: 1355251521 Enrollment ID: O20031208000678 |
News Archive
New research pertaining to the latest findings on the effects of epilepsy on both the mother and child were presented at the American Epilepsy Society's 67th Annual Meeting in Washington DC. These studies explore folic acid use, the effect of surgery with intractable focal epilepsy, and antiepileptic drug exposure during breastfeeding.
Dr. Akhilesh K. Gaharwar, associate professor, has developed a highly printable bioink as a platform to generate anatomical-scale functional tissues. This study was recently published in the American Chemical Society's Applied Materials and Interfaces.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject "mid strength" dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.
According to current estimates, 20 to 25 million Americans have or will develop gallstones, representing almost 15% of adults. Although only a small percentage of individuals with gallstones develop symptoms, more than 700,000 individuals annually undergo surgical gallbladder removal and many more take medications to manage the condition or undergo stone-dissolving procedures.
› Verified 1 days ago
| Entity Name | Ridgeview Pathology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174086581 PECOS PAC ID: 2163755786 Enrollment ID: O20190612002917 |
News Archive
New research pertaining to the latest findings on the effects of epilepsy on both the mother and child were presented at the American Epilepsy Society's 67th Annual Meeting in Washington DC. These studies explore folic acid use, the effect of surgery with intractable focal epilepsy, and antiepileptic drug exposure during breastfeeding.
Dr. Akhilesh K. Gaharwar, associate professor, has developed a highly printable bioink as a platform to generate anatomical-scale functional tissues. This study was recently published in the American Chemical Society's Applied Materials and Interfaces.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject "mid strength" dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.
According to current estimates, 20 to 25 million Americans have or will develop gallstones, representing almost 15% of adults. Although only a small percentage of individuals with gallstones develop symptoms, more than 700,000 individuals annually undergo surgical gallbladder removal and many more take medications to manage the condition or undergo stone-dissolving procedures.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Andrew Benedict, DO 1400 N 500 E, Logan, UT 84341-2455 Ph: () - | Mark Andrew Benedict, DO 1400 N 500 E, Logan, UT 84341-2455 Ph: (435) 716-4103 |
News Archive
New research pertaining to the latest findings on the effects of epilepsy on both the mother and child were presented at the American Epilepsy Society's 67th Annual Meeting in Washington DC. These studies explore folic acid use, the effect of surgery with intractable focal epilepsy, and antiepileptic drug exposure during breastfeeding.
Dr. Akhilesh K. Gaharwar, associate professor, has developed a highly printable bioink as a platform to generate anatomical-scale functional tissues. This study was recently published in the American Chemical Society's Applied Materials and Interfaces.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject "mid strength" dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.
According to current estimates, 20 to 25 million Americans have or will develop gallstones, representing almost 15% of adults. Although only a small percentage of individuals with gallstones develop symptoms, more than 700,000 individuals annually undergo surgical gallbladder removal and many more take medications to manage the condition or undergo stone-dissolving procedures.
› Verified 1 days ago
Dr. Matthew M Kershisnik, MD Pathology Medicare: Medicare Enrolled Practice Location: 1400 N 500 E, Logan, UT 84341 Phone: 435-716-5375 Fax: 843-284-3401 |